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Abstract
Background: Numerous genome-wide association studies (GWAS) conducted to date revealed genetic variants
associated with various diseases, including breast and prostate cancers. Despite the availability of these large-scale
data, relatively few variants have been functionally characterized, mainly because the majority of single-nucleotide
polymorphisms (SNPs) map to the non-coding regions of the human genome. The functional characterization of
these non-coding variants and the identification of their target genes remain challenging.
Results: In this communication, we explore the potential functional mechanisms of non-coding SNPs by integrating
GWAS with the high-resolution chromosome conformation capture (Hi-C) data for breast and prostate cancers. We
show that more genetic variants map to regulatory elements through the 3D genome structure than the 1D linear
genome lacking physical chromatin interactions. Importantly, the association of enhancers, transcription factors, and
their target genes with breast and prostate cancers tends to be higher when these regulatory elements are mapped
to high-risk SNPs through spatial interactions compared to simply using a linear proximity. Finally, we demonstrate
that topologically associating domains (TADs) carrying high-risk SNPs also contain gene regulatory elements whose
association with cancer is generally higher than those belonging to control TADs containing no high-risk variants.
Conclusions: Our results suggest that many SNPs may contribute to the cancer development by affecting the
expression of certain tumor-related genes through long-range chromatin interactions with gene regulatory elements.
Integrating large-scale genetic datasets with the 3D genome structure offers an attractive and unique approach to
systematically investigate the functional mechanisms of genetic variants in disease risk and progression.
Keywords: 3D genome structure, Genetic variation, Single-nucleotide polymorphism, Gene regulation, Chromosome
conformation capture, Genome-wide association study, Topologically associating domains, Transcription factors,
Enhancers, Breast cancer, Prostate cancer
Background
Cancer is a complex disease involving strong interactions between genetic and environmental factors, and
the second leading cause of death globally [1, 2]. The
dysregulation of oncogenes and/or tumor suppressor
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genes has an impact on cell proliferation and apoptosis
in cancer pathogenesis through genetic alterations such
as mutations [3, 4]. Further, the chromatin structure and
regulatory elements can dysregulate gene expression subsequently leading to cancer development [5, 6]. Among
different types of tumors, breast and prostate cancers
create significant health problems worldwide because of
their high incidence, health-related costs, and mortality
rates [7, 8]. Breast cancer is the most predominant malignancy in women with a high incidence rate, prevalence,
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and mortality [9–11]. The extremely complex and heterogenous etiology of breast cancer, involving numerous
components such as endocrine and environmental factors, other medical conditions, and genetic susceptibility [12, 13], is not yet fully understood. Prostate cancer is
the second most frequent tumor in men worldwide [14].
Similar to breast cancer, it has a high genetic heritability
with ethnic and geographical factors having a significant
effect on the disease progression as well [15].
Genome-wide association study (GWAS) provides a
systematic way to identify genetic risk factors for various
diseases, including cancer [16], type 2 diabetes [17], Alzheimer’s disease [18], inflammatory bowel disease [19],
and many others. The goal of GWAS is to reveal genotype-phenotype associations by detecting genomic loci
that are common and low-penetrant in a specific disease
state without any prior knowledge of their locations and
functions [20, 21]. In the last decade, GWAS conducted
on many different tumor types, including pancreatic [22],
ovarian [23], lung [24], prostate [25], and breast cancer
[26], identified numerous risk alleles, most of which are
common and individually confer only a modest increase
in disease risk. For instance, GWAS revealed 31 novel
genetic susceptibility loci associated with the genetic predisposition for breast cancer [27] and 12 novel loci for
prostate cancer [28]. Notably, the vast majority of genetic
variants identified through GWAS (> 90%) are located in
the non-coding regions of the genome [29]. These variants can provide useful insights into mechanisms responsible for the development and progression of various
diseases through the alteration of regulatory elements,
such as transcription factors (TFs) and active enhancers,
affecting the expression of certain disease-related genes
[30, 31].
A number of studies investigated the downstream
effects of a single-nucleotide polymorphism (SNP)
in disease states [32–35]. One of the first reports was
focused on a single nucleotide substitution in the promoter region of β-thalassemic globin gene decreasing the
expression of β-globin in patients with thalassemia [36].
Other studies investigated the effect of SNPs located in a
promoter region on the promoter activity [37] as well as
those located at TF binding sites affecting the binding of
TFs and, subsequently, altering the gene expression [38].
Although the presence of SNPs in the non-coding regions
of the genome, such as introns and intergenic regions,
can alter the susceptibility to disease, the exact regulatory
mechanisms of gene expression are often not fully elucidated [39, 40]. This difficulty can be attributed to the fact
that SNPs may affect the expression of genes located even
hundreds of kilobase pairs (kbp) away complicating the
illumination of cis-regulatory mechanisms [31, 41]. Deciphering the effects of high-risk SNPs is not only critical
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to understand the molecular pathogenesis of cancer, but
it can also improve cancer diagnostics and prognosis
[42], and reveal potentially novel targets for pharmacotherapy [43].
Traditionally, the genome has intensively been studied as a unidimensional, linear entity often using the
number of base pairs as a distance between various
genomic elements. More recently, the three-dimensional
(3D) structure of the genome started drawing significant attention because the regulation of gene expression and, consequently, cellular functions in physiology
and disease cannot be grasped without considering the
genome organization and the nuclear architecture. Highresolution chromosome conformation capture (Hi-C) is
the latest variant of chromosome confirmation capture
(3C) techniques developed to investigate the 3D genome
structure using next-generation sequencing strategies
[44]. This method enables researchers to profile pairread contacts in all-versus-all manner in order to calculate the interaction frequency both within chromosomes
(intra-chromosomal contacts) and between different
chromosomes (inter-chromosomal contacts). The Hi-C
resolution is determined based on the fragmentation
of chromosomes and can vary from a low resolution of
1000 kbp to as high as 5 kbp, in which each fragment
comprises 5000 base pairs [45]. Further, the genome is
systematically arranged into topologically associating
domains (TADs) defined as those genomic regions forming numerous self-interactions whose frequency is much
higher compared to contacts with other parts of the same
chromosome [46, 47]. TADs often contain multiple genes
and regulatory elements, and have been shown to play a
crucial role in the development of a wide array of diseases
including cancer [48, 49]. Overall, the Hi-C data give
invaluable insights into the 3D genome structure facilitating the identification of physical interactions among
genetic variants, regulatory elements, and their corresponding target genes.
In situ Hi-C [50] was recently combined with wholegenome bisulfite sequencing at base resolution [51] to
simultaneously profile chromatin conformation and
DNA methylation in single cells [52]. Interestingly, this
study revealed not only the coordinated DNA methylation status between distal genomic segments located in a
spatial proximity in the nucleus, but also the heterogeneity of the chromatin architecture and the DNA methylome in a mixed population of cells. Integrating Hi-C with
DNA methylation detection opens up a possibility to
simultaneously characterize the cell-type-specific chromatin organization and epigenome in complex tissues.
Other studies investigated the genetic variation related to
human diseases in the context of the 3D genome structure assembled from the Hi-C data [53, 54]. For example,

Osman et al. BMC Genomic Data

(2022) 23:13

the Hi-C data have been collected for different cancer
types in order to gain new insights into the effects of
SNPs on regulatory elements leading to tumor progression. This approach can help identify high-risk mutations
modulating gene expression in cancer by affecting regulatory elements located far away from their target genes in
the linear genome [55–57].
The Hi-C data are often used in conjunction with the
expression quantitative trait loci (eQTL) analysis to
reveal risk loci contributing to cancer progression. For
instance, the rs2981579 variant maps to the transcription
start site of fibroblast growth factor receptor 2 (FGFR2)
forming interaction peaks with several distal fragments
[58]. These regions are located hundreds kbp from the
capture region and co-localize with DNAse I hypersensitive sites, CTCF, FOXA1, GATA3, and ERα binding
sites in breast cancer and normal breast epithelial cell
lines. Translating these interactions helped explain the
association of this SNP with FGFR2 gene regulation in
breast cancer. Another example is rs4442975 associated
with the susceptibility to breast cancer. According to the
Hi-C data, this variant is located near a transcriptional
enhancer forming physical interactions with the promoter region of insulin-like growth factor binding protein 5 (IGFBP5) [59]. IGFBP5 displays allele-specific gene
expression with g-allele downregulating the expression of
IGFBP5 leading to the increased susceptibility to breast
cancer. Genetic variants are also associated with prostate
cancer through long-range chromatin interactions with
regulatory elements, such as the promoter regions of a
specific gene (rs10486567) [54] and active enhancers regulating the expression of multiple disease-related genes
(rs55958994) [60].
Although various studies were conducted to illuminate the effects of a specific genetic variation through
chromatin interactions with selected gene regulatory elements, functional relationships among SNPs, regulatory
elements, and disease-associated genes have not been
systematically evaluated at the level of the entire human
genome. In this communication, we present a large-scale
analysis of the Hi-C data in the context of relationships
among high-risk SNPs identified by GWAS for breast
and prostate cancers, regulatory elements including TFs
and enhancers, and genes associated with both diseases.
The results highlight the importance of including the 3D
genome structure in the investigation of the effects of
genetic variation on gene regulation in cancer.

Results
Mapping genetic variants to regulatory elements
and target genes

In this study, we compare two distinct approaches to
link genetic variants highly associated with disease, with
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a p-value of ≤5 × 10− 8 according to the GWAS data, to
regulatory elements and their target genes (Fig. 1). The
first approach, schematically shown in Fig. 1A, employs
the unidimensional (1D) genome structure to identify
those enhancers and TF binding sites located in the linear
proximity up and downstream of a SNP. In this example, a
TF binding site (green shape) is found downstream from
a SNP (red star) and an enhancer (orange rectangle) is
found upstream. For prostate cancer, the search distance
is set to 5 kbp on both sides of the SNP in order to create a SNP-centered window whose size is the same as the
resolution of the Hi-C data (10 kbp). Since the resolution
of the Hi-C data for breast cancer used in this study is
5 kbp, we search for regulatory elements located 2.5 kbp
down and 2.5 kbp upstream of a SNP. Both regulatory
elements shown in Fig. 1A affect the expression of their
target genes, either indirectly through TF (blue teardrop)
binding (genes G1–3, purple ovals) or directly (genes
G4–6, yellow ovals). The search for regulatory elements
in the linear proximity from 808 SNPs highly associated
with breast cancer identified 12 TF binding sites affecting
8 genes for 59 SNPs and 51 enhancers affecting 33 genes
for 50 SNPs. A similar search conducted for 13,447 SNPs
highly associated with prostate cancer resulted in 247 TF
binding sites affecting 180 genes for 986 SNPs and 3851
enhancers affecting 613 genes for 7641 SNPs.
The second approach maps SNPs highly associated
with cancer at a p-value of ≤5 × 10− 8 to regulatory elements located in the spatial proximity according to the
3D genome structure. Here, we utilize highly confident
intra- and inter-chromosomal contacts obtained from
the Hi-C data with a q-value of ≤0.05. Specifically, for
each SNP, we collected those DNA fragments containing at least one regulatory element and forming physical
contacts with that SNP. Next, we selected one fragment
with the lowest q-value for a contact; in case of multiple
fragments having the same lowest q-value for contacts,
the longest-range fragment from the SNP was picked.
As shown in Fig. 1B, a DNA fragment containing a disease-associated SNP (red star) physically interacts with
another fragment through a highly confident long-range
contact. In this example, the interacting fragment contains a binding site (green shape) for a TF (blue teardrop)
and an active enhancer (orange rectangle). Just as in the
first approach utilizing the 1D linear genome, these elements regulate the expression of their target genes, G1–3
(purple ovals) and G4–6 (yellow ovals), respectively.
Following this procedure, we identified 19,240 chromatin fragments forming highly confident contacts
with 808 SNPs associated with breast cancer. Selecting only one long-range chromatin contact per SNP
with the lowest q-value resulted in 702 fragments containing regulatory elements. These elements include
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Fig. 1 Schematic representation of the procedure to map SNPs to regulatory elements and target genes. The mapping is shown for A the 1D
linear genome and B the 3D genome structure constructed at the Hi-C resolution of 10 kbp. Red stars are a SNPs highly associated with a disease
at a p-value of ≤5 × 10− 8. Regulatory elements include transcription factors (TF, blue teardrops) and their binding sites (BS, green sectors), and
enhancers (orange rounded rectangles). Each regulatory element is linked to its target genes (G1–3, purple ovals for TFs and G4–6, yellow ovals for
enhancers). In (A), regulatory elements are identified within a DNA window of 10 kbp centered on the SNP, whereas in (B), regulatory elements are
identified in a DNA fragment forming a physical contact with the fragment containing the SNP

239 enhancers having 147 target genes in contact with
702 SNPs and 83 binding sites for TFs having 70 target genes in contact with 459 SNPs. Similar to breast
cancer, selecting one long-range chromatin contact per
SNP with the lowest q-value from 1,952,907 chromatin
fragments forming contacts with 13,447 SNPs associated with prostate cancer resulted in 13,429 contacts.
Among these interactions, 13,410 contacts are between
13,410 SNPs and 3585 enhancers with 747 target genes,
and 1387 contacts are between 1387 SNPs and 324
binding sites for TFs with 190 target genes.

Disease association of enhancers connected to genetic
variants in cancer

In order to measure the relevance of those regulatory
elements affected by SNPs to a disease, a series of disease association (DA) scores were computed. For each
high-risk SNP, we calculated the median DA score
for mapped enhancers and TFs as well as the median
DA score for target genes whose expression is regulated by these elements. The number of SNPs along
with quantile and inter-quantile range (IQR) values
are reported in Table 1 (enhancers) and Table 2 (TFs).
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Table 1 Disease association (DA) statistics for enhancers linked to significant SNPs in breast and prostate cancer. Statistics for
enhancers identified with 1D and 3D approaches include the number of SNPs used in the analysis, quantiles, and the inter-quantile
range (IQR). For each cancer type, DA scores for enhancers and their target genes are reported
Statistic

Breast cancer

Prostate cancer

Enhancer DA score

DA score for target gene

Enhancer DA score

DA score for target
gene

1D

3D

1D

3D

1D

3D

1D

3D
12,010

# of SNPs

50

702

50

662

7,641

13,410

7,213

1st quantile

2.69

4.61

2.1

4.3

3.74

4.59

1.9

2.6

2nd quantile

2.91

4.80

2.4

5.0

4.14

4.81

2.4

3.2

3rd quantile

3.30

5.01

2.6

5.2

4.57

5.02

3.4

3.9

IQR

0.61

0.40

0.5

0.9

0.83

0.43

1.5

1.3

Table 2 Disease association (DA) statistics for transcription factors (TFs) linked to significant SNPs in breast and prostate cancer.
Statistics for enhancers identified with 1D and 3D approaches include the number of SNPs used in the analysis, quantiles, and the
inter-quantile range (IQR). For each cancer type, DA scores for enhancers and their target genes are reported
Statistic

Breast cancer

Prostate cancer

TF DA score

DA score for target gene

Fraction of DA-TFsa

DA score for target
gene

1D

3D

1D

3D

1D

3D

1D

3D
1,387

# of SNPs

59

459

42

210

986

1,387

759

1st quantile

2.0

10.0

2.5

4.3

0.31

0.65

1.4

3.0

2nd quantile

3.0

12.0

2.7

4.7

0.33

0.67

1.9

3.2

3rd quantile

4.0

12.0

3.0

4.9

0.34

0.69

3.0

3.7

IQR

2.0

2.0

0.5

0.6

0.03

0.04

1.6

0.7

a

Fraction of disease-associated TFs within a set of all TFs linked to significant SNPs

The distribution of DA scores for active enhancers is
presented in Fig. 2. Figure 2A shows that the median
(2nd quantile) DA score of 4.80 for enhancers linked
to highly associated SNPs in breast cancer in the 3D
genome structure is higher compared to 2.91 in the
1D linear genome (Table 1). Similar to breast cancer,
Fig. 2B and Table 1 show that the median DA score
for enhancers linked to SNPs highly associated with
prostate cancer is higher in 3D (4.81) than 1D (4.14).
To further corroborate these results, we computed DA
scores for target genes whose expression is affected by
enhancers linked to genetic variants in cancer. Figure 3
and Table 1 show that the median DA scores are systematically higher in 3D compared to 1D in breast cancer (Fig. 3A, 2.4 for 1D and 5.0 for 3D) and in prostate
cancer (Fig. 3B, 2.4 for 1D and 3.2 for 3D). In addition
to higher DA scores, IQRs are typically smaller in the
3D genome structure compared to 1D (Table 1), for
instance, the IQR for the enhancer DA score is 0.40 in
3D and 0.61 in 1D for breast cancer, and 0.43 in 3D and
0.83 in 1D for prostate cancer.

Disease association of transcription factors connected
to genetic variants in cancer

Next, we analyze the disease association of TFs linked
to SNPs highly associated with cancer (Fig. 4) and their
target genes (Fig. 5) with statistics reported in Table 2.
The distribution of DA scores for TFs mapped to breast
cancer is presented in Fig. 4A. Here, the median DA
score of 12.0 in the 3D genome structure is higher than
3.0 in 1D. In addition, Fig. 5A shows that the median
DA score of TF target genes is also higher in 3D (4.7)
compared to 1D (2.7). In the absence of numerical DA
scores for TFs linked to SNPs highly associated with
prostate cancer, we conducted the analysis using the
fraction of disease-associated TF (Fig. 4B). On average,
about two-thirds of TF mapped to SNPs in 3D are disease-associated, whereas this fraction is only one-third
in 1D. Further, Fig. 5B shows that the median DA score
of the corresponding target genes is higher in 3D (3.2)
than in 1D (1.9). In contrast to active enhancers, IQRs
for TFs are similar between 1D and 3D, except for the
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Fig. 2 Distribution of disease-association (DA) scores for enhancers linked to SNPs. Enhancers were identified by mapping SNPs highly associated
with A breast and B prostate cancer in the unidimensional (1D, purple violins) and the three-dimensional (3D, yellow violins) genome structure. In
each violin, the horizontal black line is the median, the narrow gray box shows the first and third quantiles, and whiskers mark the minimum and
maximum values excluding outliers, which are represented by black diamonds

Fig. 3 Distribution of disease-association (DA) scores for the target genes of enhancers linked to SNPs. Enhancers were first identified by mapping
SNPs highly associated with A breast and B prostate cancer in the unidimensional (1D, purple violins) and the three-dimensional (3D, yellow violins)
genome structure, and then linked to their target genes. In each violin, the horizontal black line is the median, the narrow gray box shows the first
and third quantiles, and whiskers mark the minimum and maximum values excluding outliers, which are represented by black diamonds
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Fig. 4 Analysis of the disease association of transcription factors (TFs) linked to SNPs. A The distribution of disease-association (DA) scores for TFs
linked to SNPs highly associated with breast cancer. B The fraction of disease-associated TFs linked to SNPs highly associated with prostate cancer.
TFs were identified by mapping SNPs in the unidimensional (1D, purple violins) and the three-dimensional (3D, yellow violins) genome structure.
In each violin, the horizontal black line is the median, the narrow gray box shows the first and third quantiles, and whiskers mark the minimum and
maximum values excluding outliers, which are represented by black diamonds

Fig. 5 Distribution of disease-association (DA) scores for the target genes of transcription factors (TFs) linked to SNPs. TFs were first identified by
mapping SNPs highly associated with A breast and B prostate cancer in the unidimensional (1D, purple violins) and the three-dimensional (3D,
yellow violins) genome structure, and then mapped to their target genes. In each violin, the horizontal black line is the median, the narrow gray
box shows the first and third quantiles, and whiskers mark the minimum and maximum values excluding outliers, which are represented by black
diamonds
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Fig. 6 Case studies for genetic variants related to breast cancer. The possible effects of SNPs on the expression of A MAP3K1, B FGFR2, and C CDYL2
genes are presented in the context of the 3D genome structure. Red stars are SNPs highly associated with a disease at a p-value of ≤5 × 10− 8
affecting regulatory elements through long-range physical interactions according to dashed black arrows. Dashed gray arrows link regulatory
elements, including transcription factors (blue teardrops) and their binding sites (BS, green sectors), and enhancers (orange rounded rectangles)
to target genes (purple ovals). Chromatin fragments from the Hi-C data (gray double helices) annotated with their start and end coordinates are
connected by solid black lines showing their order in the linear genome

distribution of DA scores for TF target genes in prostate cancer (1.6 and 0.7, respectively, Table 2).
Examples of gene regulation through chromatin
interactions in breast cancer

We present several case studies in order to illustrate
the significance of the 3D genome structure in linking
genetic variation to gene regulation in breast cancer
(Fig. 6). The locations of genomic elements discussed
in this section and their association with breast cancer
are provided in Supplementary Tables S1-S3. The first
example is mitogen-activated protein kinase kinase
kinase 1 (MAP3K1), a serine/threonine kinase known to
play an important role in different functions of the cell
[61, 62]. MAP3K1 can be activated by different stimuli, such as cytokines and growth factors, that constitute a complex signaling network controlling a diverse
array of cellular functions [63]. In addition to numerous studies focused on somatic mutations in MAP3K1
[64–66], GWAS revealed associations between SNPs,
including rs7714232 and rs16886272 regulating the
expression of MAP3K1, and breast cancer [67, 68].
Further, multiple transcription factors, such as ER-α,
FOXA1 and GATA3, were shown to upregulate the
expression of MAP3K1 through long range chromatin
interactions [67]. Figure 6A shows that rs7714232 at
position Chr5:56,011,357 is in contact with a chromatin
fragment containing an active enhancer 119,861, and
rs16886272 at position Chr5:56,067,434 is in contact
with a fragment containing a putative binding site for
transcription factor GATA3 predicted with a p-value of
2.2 × 10− 5. Enhancer 119,861 is associated with breast
cancer at a p-value of 2.4 × 10− 5 and GATA3 has a high

disease association score of 5.9. MAP3K1, which itself
has a high disease association score of 5.3, is a target
gene for both regulatory elements. Thus, rs7714232
and rs16886272 may indirectly affect the expression of
MAP3K1 through physical interactions with an active
enhancer and a transcription factor binding site.
Fibroblast growth factor receptor 2 (FGFR2) belonging
to the receptor tyrosine kinase family mediates the cellular signaling and plays important roles in the developmental induction, cell growth and differentiation, and
cell fate [69–71]. Several studies reported the association
between mutations affecting FGFR2 and breast cancer
[72, 73]. For example, multiple SNPs located in the second intron of FGFR2 cause the increased expression of
FGFR2 linked to cancer progression [74]. Another study
reported an association between the expression of FGFR2
and the number of breast tumor initiating cells [75].
GWAS data revealed the association between FGFR2
genetic variants and the risk of breast cancer [72, 76], for
instance, rs4752575 was shown to alter the expression of
FGFR2 leading to the increased susceptibility to breast
cancer [77]. Figure 6B shows that rs4752575 located at
position Chr10:123,407,187 physically interacts with a
chromatin fragment containing multiple transcription
factor binding sites, including a putative binding site
for forkhead box protein A1 (FOXA1) predicted with a
p-value of 4.5 × 10− 4. FOXA1 is highly associated with
breast cancer with a score of 5.8 and was identified as
one of the master regulators of FGFR2 [78]. According to
these data, we propose a new model explaining the high
association of rs4752575 with breast cancer at a p-value
of 5.5 × 10− 9. Specifically, rs4752575 may dysregulate the
expression of FGFR2 through the chromatin interaction

Osman et al. BMC Genomic Data

(2022) 23:13

with the binding site for FOXA1, a master regulator of
the FGFR2 gene.
Chromodomain Y-like protein 2 (CDYL2) is a putative epigenetic factor belonging to a family of proteins
characterized by the presence of N-terminal chromodomain that binds methylated histones H3K9 and H3K27
[79–81]. CDYL2 has been identified as either a tumor
suppressor or oncogene depending on the cancer type
[82, 83]. Moreover, CDYL2 was reported to be overexpressed in breast cancer supporting its role in disease
progression [84]. The transcript variants of CDYL2 were
found to be differently associated with breast cancer,
suggesting a new therapeutic strategy targeting specific
CDYL2 isoforms [85]. Several genetic variants related
to CDYL2 have been identified by GWAS to be associated with breast cancer progression and development,
including rs13329835 found in the intergenic region
of CDYL2 gene [86, 87]. Another variant, rs9940301, at
position Chr16:80,641,906 is strongly associated with
breast cancer progression in women of African ancestry
with a p-value of 2.0 × 10− 9 [88]. According to the Hi-C
data (Fig. 6C), rs9940301 is in contact with a chromatin
fragment containing three putative enhancers, 2,317,260,
2,317,262, and 2,317,263, all associated with breast cancer with a p-value of 9.0 × 10− 6. These enhancers activate
the expression of the CDYL2 gene suggesting a new association mechanism between rs9940301 and breast cancer
through physical interactions with enhancers regulating
CDYL2 gene expression.
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Examples of gene regulation through chromatin
interactions in prostate cancer

Figure 7 presents selected cases demonstrating how the
genetic variation in prostate cancer can be linked to gene
regulation by analyzing the 3D genome structure. The
locations of genomic elements discussed in this section
and their association with prostate cancer are provided
in Supplementary Tables S1-S3. Androgen receptor (AR)
is a master regulator belonging to the nuclear receptor
superfamily [89]. It acts as a transcription factor binding a specific ligand molecule to control the expression of
targeted genes [90]. Prostate function primarily depends
on the androgen signaling axis through the regulation of
AR target genes [91]. AR is highly associated with prostate cancer with a score of 8.0, which is consistent with
observations that it is often overexpressed in prostate
cancer [92] and mutations in the AR gene are present
in a large population of castration-resistant prostate
cancer patients [93, 94]. The GWAS data revealed that
numerous SNPs near the AR locus are associated with
prostate cancer [95, 96]. For instance, rs6152 is located
in the first exon of the AR gene and it is associated
with a susceptibility to prostate cancer at a p-value of
1.5 × 10− 12 [97, 98]. We also found that rs6152 at position
ChrX:66,765,627 forms a contact with a chromatin fragment containing an active enhancer 2,765,787 associated
with prostate cancer at a p-value of 1.6 × 10− 2 and affecting the expression of AR (Fig. 7A). Thus, the physical
interaction between rs6152 and an enhancer may play a

Fig. 7 Case studies for genetic variants related to prostate cancer. The possible effects of SNPs on the expression of A AR, B POU5F1B, and C OXT1
and EHBP1 genes are presented in the context of the 3D genome structure. Red stars are SNPs highly associated with a disease at a p-value of
≤5 × 10− 8 affecting regulatory elements through long-range physical interactions according to dashed black arrows. Dashed gray arrows link
regulatory elements, including transcription factors (blue teardrops) and their binding sites (BS, green sectors), and enhancers (orange rounded
rectangles) to target genes (purple ovals). Chromatin fragments from the Hi-C data (gray double helices) annotated with their start and end
coordinates are connected by solid black lines showing their order in the linear genome
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role in the regulation of AR gene expression during prostate cancer progression.
Octamer-binding transcription factor 4 (OCT4), a
member of the POU domain-containing family of transcription factors, is expressed in embryonic and adult
stem cells [99]. Although six different pseudogenes identified for OCT4 are not expressed, these elements are
believed to play a role in the regulation of OCT4 expression [100, 101]. Interestingly, two of these OCT4 pseudogenes, POU5F1P5 and POU5F1B, were found to be
transcribed in cancer cells [102]. POU5F1B was shown
to be overexpressed in gastric cancer and its knockdown confirmed a role for POU5F1B in the promotion
of tumor cell growth [103]. Further, the methylation level
near the POU5F1B gene [104] and the genetic variation
around that region [105] were found to be associated
with the prostate cancer risk. For instance, rs6983267 was
reported to be in linkage disequilibrium with the openreading frame of the POU5F1B gene among people of
European ancestry and associated with the expression of
POU5F1B in prostate of white subjects [106]. Located at
position Chr8:128,413,305, rs6983267 is associated with
prostate cancer at a p-value of 2.8 × 10− 141. Figure 7B
shows that it is also in contact with a chromatin fragment
containing multiple putative transcription factor binding
sites including a confidently predicted binding site for AR
with a p-value of 3.5 × 10− 4, which regulates the expression of POU5F1B. According to these findings, rs6983267
may play a role in regulating PO5F1B expression by
affecting the binding of AR to its binding site.
EH domain-binding protein 1 (EHBP1) gene encodes
Eps15 homology domain binding protein playing a role
in endocytic trafficking [107]. Recently, GWAS reported
the association of a genetic variant rs721048, located
within one of the introns of the EHBP1 gene, and the susceptibility to prostate cancer [28, 108] with a p-value of
5.0 × 10− 22. Interestingly, Fig. 7C shows that rs721048 at
position Chr2:63,131,731 forms a contact with a chromatin fragment containing an active enhancer 406,774 associated with prostate cancer at a p-value of 1.5 × 10− 4 that
regulates the expression of EHBP1. Further, enhancer
406,774 also regulates the expression of orthodenticle
homeobox 1 (OTX1), a transcription factor playing a critical role in multiple developmental processes, such as the
neuronal differentiation [109]. Several studies reported
the hypermethylation of the OTX1 gene promoter region
in non-small lung cancer [110, 111] and an altered OTX1
expression in medulloblastoma and other brain tumors
[112]. It is important to note that the expression of OTX1
is also associated with prostate cancer risk [113]. Further,
OTX1 is one of several transcription factors involved in
tumor-specific enhancer networks and it was found to be
linked to active enhancers in prostate adenocarcinoma
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[114]. Our data suggest that rs721048 may be associated with prostate cancer through the disruption of the
mechanism of action of certain tumor-specific enhancers
causing the dysregulation of the expression of OTX1 and
EHBP1 genes.
Mapping genetic variants to topologically associating
domains

Next, TADs were identified from the Hi-C data and all
regulatory elements and SNPs were mapped to these
domains as shown in Fig. 8. Based on the presence of
SNPs highly associated with cancer, the resulting TADs
are divided into two groups, TADs containing no SNPs
(control, Fig. 8A) and TADs containing at least one SNP
with a p-value of ≤5 × 10− 8 according to the GWAS
data (SNP-rich, Fig. 8B). Specifically, we identified the
total of 21,157 TADs from the Hi-C data for breast cancer, including 30 TADs enriched with disease-associated SNPs. Among 30 SNP-rich TADs, 26 also contain
enhancers (477 in total) and 17 contain TF binding sites
(36 in total). The control dataset for breast cancer comprises 16,473 TADs containing 259,780 enhancers and
10,463 TADs containing 23,890 binding sites for TFs. In
addition, the total of 17,435 TADs were detected from
the Hi-C data for prostate cancer, including 304 TADs
enriched with disease-associated SNPs; 291 of these
SNP-rich TADs contain enhancers (7940 in total) and
241 contain TF binding sites (686 in total). The control
dataset for prostate cancer comprises 13,587 TADs containing 250,789 enhancers and 10,070 TADs containing
22,562 binding sites for TFs.
We first take a glance at selected genetic variants highly
associated with breast (4 SNPs) and prostate (3 SNPs)
cancers discussed above in order to determine whether
gene regulatory elements located in their spatial proximity according to the Hi-C data reside in the same TAD.
Interestingly, this holds true in almost all cases. Both variants rs7714232 and rs16886272 associated with breast
cancer, enhancer 119,861, and a binding site for transcription factor GATA3 are located in TAD 6450 whose
boundaries are Chr5:56,010,000 – Chr5:56,140,000. Further, variant rs9940301 along with all three enhancers,
2,317,260, 2,317,262, and 2,317,263, reside in the same
TAD 17447 (Chr16:80,630,000 – Chr16:80,950,000).
Variant rs4752575 and FOXA1 binding site belong
to neighboring TADs 12,498 (Chr10:123,360,000 –
Chr10:123,460,000) and 12,497 (Chr10:123,330,000
– Chr10:123,360,000), respectively. In prostate cancer, TAD 1830 (Chr2:63,010,000 – Chr2:63,160,000)
contains both rs721048 and enhancer 406,774, TAD
8618 (Chr8:128,410,000 – Chr8:128,490,000) contains
both rs6983267 and AR binding site, and TAD 16953
(ChrX:66,530,000 – ChrX:67,270,000) contains both
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Fig. 8 Schematic representation of topologically associating domains (TADs). Red stars are SNPs highly associated with a disease at a p-value of
≤5 × 10− 8, orange rounded squares represent enhancers, green circles represent transcription factors, and blue square brackets show the location
of TAD boundaries. TADs are divided into two groups, A control TADs containing no highly associated SNPs and B SNP-rich TADs carrying at least
one highly associated variant

rs6152 and enhancer 2,765,787. On that account, we
expect TADs enriched in disease-associated SNPs to also
contain those gene regulatory elements having higher
disease association compared to control TADs, which is
investigated in the following section.

similar between SNP-rich and control TADs in both cancers. These results demonstrate that disease-associated
genetic variants and gene regulatory elements indeed
tend co-localize within certain TADs identified based on
the 3D genome structure.

Association of SNPs and regulatory elements with cancer
in the context of TADs

Discussion
Although a large number of genetic variants associated
with cancer have been identified by GWAS, the exact
mechanisms by which these mutations affect the phenotype have not yet been fully elucidated. A significant
challenge in explaining the functional mechanisms of
SNPs in cancer initiation and progression arises from the
fact that the vast majority of disease-associated variants
are located within the non-coding regions of the genome.
Non-coding SNPs are thought to exert their pathological effects by altering gene regulation rather than directly
affecting the sequence, structure, and function of gene
products. Accumulated data on the 3D genome structure
collected from Hi-C experiments offer a unique opportunity to investigate the effects of genetic variation, particularly those located in the non-coding complement of
the human genome, on gene regulation leading to cancer
pathophenotypes. In this communication, we integrated
the large-scale data provided by GWAS with the information on chromatin structure and interactions in breast
and prostate cancers in order to systematically evaluate the effects of SNPs on gene regulatory mechanisms.
We are specifically interested in the comparison of this
3D method utilizing the Hi-C data to a 1D proximity

In order to verify the assertion that those TADs carrying genetic variants highly associated with cancer also
contain gene regulatory elements whose disease association is high, we first calculated DA scores for enhancers
located within control and SNP-rich TADs. The distribution of DA scores is shown in Fig. 9 with the corresponding statistics reported in Table 3. Compared to
a median DA score of 4.75 for control TADs in breast
cancer, SNP-rich TADs contain enhancers with a higher
median DA score of 5.66 (Fig. 9A). A median DA score
of 5.66 for enhancers located in SNP-rich TADs is higher
than a value of 4.69 for those belonging to control TADs
in prostate cancer as well (Fig. 9B). Similar to enhancers,
Fig. 10 shows the distribution of DA scores computed
for TFs residing in SNP-rich and control TADs with the
corresponding statistics reported in Table 3. In breast
cancer, the median DA score of 11.5 for TFs located in
control TADs is lower than a value of 17.0 for those present in SNP-rich TADs, whereas in prostate cancer, the
fraction of disease-associated TFs in SNP-rich TADs
is twice as high as in control TADs (Fig. 10B). Further,
Table 3 shows that IQRs for enhancers and TFs are very
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Fig. 9 Distribution of disease-association (DA) scores for enhancers within TADs. DA scores against A breast and B prostate cancer are calculated for
enhancers present in control (blue violins) and SNP-rich (green violins) TADs. In each violin, the horizontal black line is the median, the narrow gray
box shows the first and third quantiles, and whiskers mark the minimum and maximum values excluding outliers, which are represented by black
diamonds

Table 3 Disease association (DA) statistics for enhancers and transcription factors (TFs) within TADs in breast and prostate cancer.
TADs are divided into two groups, containing no SNPs with a significant association to disease (control) and those containing at least
one SNP with a significant disease association (SNP-rich). Statistics include the number of TADs used in the analysis, quantiles, and the
inter-quantile range (IQR)
Statistic

Breast cancer

Prostate cancer

Enhancer DA score

TF DA score

Control

Control

SNP-rich

SNP-rich

Enhancer DA score

Fraction of DA-TFsa

Control

Control

SNP-rich

SNP-rich

# of TADs

16,473

26

10,463

17

13,587

291

10,070

241

1st quantile

4.55

5.42

10.5

17.0

4.50

5.42

0.32

0.66

2nd quantile

4.75

5.66

11.5

17.0

4.69

5.66

0.33

0.67

3rd quantile

4.90

5.80

12.5

18.0

4.87

5.77

0.35

0.69

IQR

0.35

0.38

2.0

1.0

0.37

0.35

0.03

0.03

a

Fraction of disease-associated TFs within TADs

approach assuming that genetic variants affect regulatory elements located down- and up-stream in the linear
DNA.
Focusing on SNPs highly associated with breast and
prostate cancers, we conducted a comprehensive analysis
of their relationships to various enhancers and binding
sites for transcription factors regulating the expression
of their target genes. Considering a vast body of evidence
supporting the association of many regulatory elements

with cancer phenotypes, we propose that genetic variants forming physical contacts with these elements may
contribute to the development and progression of disease
by altering the expression levels of cancer-related genes.
There are several benefits of including the Hi-C data in
the analysis of the effects of genetic variation on gene
expression. The 3D genome structure allows for a more
efficient mapping between variants and regulatory elements compared to the unidimensional genome lacking
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Fig. 10 Analysis of the disease association of transcription factors (TFs) within TADs. A The distribution of disease-association (DA) scores against
breast cancer and B the fraction of TFs associated with prostate cancer. Blue violins show the distribution of DA scores and the fraction within
control TADs, whereas green violins show the distribution within SNP-rich TADs. In each violin, the horizontal black line is the median, the narrow
gray box shows the first and third quantiles, and whiskers mark the minimum and maximum values excluding outliers, which are represented by
black diamonds

physical chromatin interactions [115, 116]. Importantly,
the disease association scores of enhancers and transcription factors mapped to cancer-associated SNPs
through chromatin contacts are consistently higher compared to those identified using a linear DNA model. This
also holds true for the target genes of these regulatory
elements.
Our results are in line with numerous studies demonstrating that the 3D structure of the genome, which
facilitates certain DNA-DNA interactions regulating
gene expression [117], can effectively be used to reveal
the functional mechanisms of genetic variation as well
as candidate genes related to cancer [118]. For instance,
potentially functional non-coding mutations were identified by integrating cancer genome variation with cisregulatory networks, long-range chromatin interactions,
and transcriptomic data [119]. This study demonstrated
that frequently mutated regulatory elements not only
show long-range chromatin interactions and mRNA
abundance associations with target genes, but also are
enriched in motif-rewiring mutations and structural
variants. Another research characterized the mutational
landscape of gene-regulatory and chromatin architectural
elements in whole cancer genomes with transcriptional
and pathway activity, functional conservation and recurrent driver events [120]. A statistical model to quantify

mutational enrichment or depletion in classes of genomic
elements through megabase-scale effects revealed that an
increased mutation frequency in transcription start sites
associates with mRNA abundance in most cancer types,
while open-chromatin regions are generally enriched in
mutations.
We finally investigated the relationship among genetic
variants, regulatory elements, and their target genes in
the context of TADs, relatively small, compact, and selfinteracting genomic regions [121]. As anticipated, we
found that those TADs carrying cancer-associated SNPs
also contain enhancers and binding sites for transcription factors whose disease association is generally higher
compared to regulatory elements located in control
TADs devoid of high-risk SNPs. This analysis can further
be expanded to include genome-wide epigenome patterns highlighting an important role of the DNA methylation in the maintenance of 3D genome regulation.
Interestingly, DNA methylation was found to intrinsically
modulate chromatin structure and function by increasing chromatin condensation in peri-centromeric regions,
decreasing the overall DNA flexibility, and favoring the
heterochromatin state [122]. Further, it has been shown
that cancer-related methylation loss is associated with
the deregulation of 3D genome organization leading
to the disruption of the genome compartmentalization
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[123]. DNA methylation can also inactivate TAD boundaries leading to the concomitant activation of key cancer
drivers by enhancers located outside their normal TADs
through long-range chromatin interactions [124].
Integrating the chromatin structure with the multiomics data is a promising approach to study how the spatial organization of the genome affects gene regulation
through physical interactions between various genomic
regions. This technique also holds promise to not only
reveal hot spots within the human genome linked to disease, but also investigate subtle differences between the
genetic makeup of individuals leading to varying levels of
disease risk and progression. Overall, our work provides
a new perspective for investigating the effects of genetic
variation on gene regulation in cancer through the largescale analysis of long-range chromatin interactions shaping the 3D genome structure.

Methods
Hi‑C data

Hi-C data at 5 kbp resolution collected for the human
mammary epithelial cell line were downloaded from
the Gene Expression Omnibus database (GEO accession: GSE63525) [50]. The Hi-C data at 10 kbp resolution collected for the human normal prostate cell line
were downloaded from the Gene Expression Omnibus
database (GEO accession: GSM3564252) [125]. In order
to effectively detect significant chromatin contacts, statistical confidence estimates for Hi-C contact maps were
computed with the Fit-Hi-C programming application
[126]. Specifically, the latest reimplementation, FitHiC2
v2.0.7, was used to perform the genome-wide analysis
of the high-resolution Hi-C data for breast and prostate
cancers, including intra- and inter-chromosomal contacts. This software first computes binomial p-values for
the significance of observing a contact count that is at
least equal to the observed integer count value or higher.
P-values are then subjected to multiple testing correction using the Benjamini-Hochberg procedure to obtain
q-values representing the minimum false discovery rate
(FDR) threshold at which the contact is considered significant [127]. We excluded low-confidence interactions
keeping only those contacts whose q-values are ≤0.05
[128].
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cancer and 13,502,794 SNPs for prostate cancer, and then
we selected 808 (breast cancer) and 13,447 (prostate cancer) highly associated SNPs with a p-value of ≤5 × 10− 8
according to the published work [131].
Gene regulatory elements

Data on enhancers, including their genomic location, target genes, and disease association scores were obtained
from the Human Enhancer Disease Database (HEDD)
database [132]. HEDD provides comprehensive information for about 2.8 million human enhancers identified by
ENCODE, FANTOM5 and RoadMap with disease association scores based on enhancer-gene and gene-disease
associations. In this study, we used 262,490 enhancers
related to breast cancer and 267,453 enhancers related to
prostate cancer. The data on transcription factors were
obtained from the TF2DNA database containing 1306
TFs, 19,190 target genes, and 24,634,759 binding sites
[133]. From these data, 164 TFs associated with breast
cancer were selected based on an experimental and computational pipeline integrating AccessTF, a Bayesian network model to accurately predict protein-bound DNA
sequence motifs based on chromatin accessibility, with
TFScore, a scoring system that rank-orders transcription
factors as candidates for being important for a biological process [134]. Further, we identified 612 TFs associated with prostate cancer based on RegNetDriver, a novel
computational method to identify tumorigenic drivers
from the effects of coding and non-coding single nucleotide variants, structural variants, and DNA methylation
changes in the DNase I hypersensitivity based regulatory
network [135]. Disease association scores for enhancer
and TF target genes were collected from the DISEASES
database [136]. This resource provides evidence on disease-gene associations primarily computed by an automatic text mining of biomedical abstracts. A scoring
scheme employed by DISEASES also integrates other
types of evidence including manually curated diseasegene associations, cancer mutation data, and genomewide association studies from multiple databases. We
identified the total of 12,846 genes having an association
score to breast cancer and 10,032 genes having an association score to prostate cancer.

Genome‑wide association studies

Genome‑wide mapping of genetic variants to regulatory
elements

In this study, we used the GWAS data for breast cancer generated for 122,977 cases and 105,974 controls of
European ancestry and 14,068 cases and 13,104 of East
Asian ancestry [129], and for prostate cancer generated
for 46,939 cases and 27,910 controls of European ancestry [130]. We first identified SNPs having OncoArray
accession numbers resulting in 568,712 SNPs for breast

In the unidimensional approach, SNPs highly associated with breast and prostate cancer were mapped to
enhancers and TF binding sites in the linear proximity
using a 5 kbp window (2.5 kbp up and 2.5 kbp downstream from the SNP) for breast cancer and a 10 kbp
window (5 kbp up and 5 kbp downstream from the
SNP) for prostate cancer. These window sizes were
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selected to match the resolution of the Hi-C data. For
each SNP, we then calculated the median association
score of mapped enhancers and TFs as well as their
target genes with the exception of TFs in prostate cancer, for which we computed the fraction of diseaseassociated TFs. In the three-dimensional approach,
each highly associated SNP was mapped to regulatory
elements present in a chromatin fragment forming the
most confident contacts with the lowest q-value computed by the FitHiC2 software. When multiple fragments have the same lowest q-value, we selected the
longest-range interaction. This way, the same number
of chromatin fragments are utilized by both 1D and 3D
approaches. The median association scores of regulatory elements and their target genes mapped through
physical interactions were calculated in a similar manner as in the 1D analysis.
Topologically associating domains

TADs were identified from intra-chromosomal contacts
for each chromosome with TopDom v0.10.0 [137]. For
each TAD, we calculated the median association scores
for regulatory elements present in that domain as well as
for their target genes. TADs were then divided into two
groups, SNP-rich carrying at least one genetic variant
highly associated with cancer at a p-value of ≤5 × 10− 8
and control TADs containing no highly associated SNPs.
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